---
title: "HITECK released its performance for the first half of the year, with a net loss attributable to the parent company of 39.1799 million yuan, an increase of 72.10%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254484119.md"
description: "According to the Zhitong Finance APP, HITECK released its semi-annual report for 2025, showing an operating income of 275 million yuan, a year-on-year decrease of 3.36%. The net loss attributable to shareholders of the listed company was 39.1799 million yuan, a year-on-year increase of 72.10%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 57.4759 million yuan, a year-on-year increase of 22.19%. The basic loss per share was 0.3 yuan"
datetime: "2025-08-25T16:18:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254484119.md)
  - [en](https://longbridge.com/en/news/254484119.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254484119.md)
---

# HITECK released its performance for the first half of the year, with a net loss attributable to the parent company of 39.1799 million yuan, an increase of 72.10%

According to the Zhitong Finance APP, HITECK (300683.SZ) released its semi-annual report for 2025, reporting an operating income of 275 million yuan, a year-on-year decrease of 3.36%. The net loss attributable to shareholders of the listed company was 39.1799 million yuan, a year-on-year increase of 72.10%. The net loss attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 57.4759 million yuan, a year-on-year increase of 22.19%. The basic loss per share was 0.3 yuan

### Related Stocks

- [300683.CN](https://longbridge.com/en/quote/300683.CN.md)

## Related News & Research

- [FDA green lights more screwworm medications: Should you give them to your pets?](https://longbridge.com/en/news/296002089.md)
- [Rhelion signs supply license with Toronto’s UHN for psilocybin trial in Parkinson’s depression](https://longbridge.com/en/news/296134949.md)
- [Faeth Therapeutics wins FDA fast-track status for PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer](https://longbridge.com/en/news/296098241.md)
- [Pieverse: Purr-Fect Claw goes live on LINE - 15 Aug 2026](https://longbridge.com/en/news/296002936.md)
- [Primary Hydrogen Enters Nova Scotia's Cumberland Basin Natural Hydrogen District with Staking of the Northumberland Project | HNATF Stock News](https://longbridge.com/en/news/296125091.md)